All In Biotech

Drug Trial Radar · NCT06475495

Comparison of B-cell Depletion by Rituximab and Anti-CD 19 CAR-T Therapy in Patients With Rheumatoid Arthritis

Comparison of B-cell Depletion by Rituximab and Anti-CD 19 CAR-T Therapy in Patients With Rheumatoid Arthritis. Two-stage Interventional, Prospective, Randomized, Controlled, Open Label, Parallel-group Phase I/II Trial in Patients With Active, ACPA-positive and Treatment Refractory Rheumatoid Arthritis

Last checked: Nov 19, 2026Latest source record: Mar 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

13

Planned (sponsor's estimate)

Start

Dec 4, 2024

Primary completion

Jun 2027

Study completion Jun 2027

Sponsor

Lead sponsor
Charite University, Berlin, GermanyAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Kyverna Therapeutics
First posted
Jun 26, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this phase I/II clinical trial is to compare B-cell depletion by rituximab and anti-CD 19 CAR-T therapy in patients with rheumatoid arthritis. The main questions it aims to answer are: * To assess the safety of anti-CD19 CAR T cell therapy in subjects with active, ACPA positive and treatment refractory RA (Phase-I) * To assess the safety of anti-CD19 CAR T cell therapy and of rituximab in subjects with active, ACPA positive and treatment refractory RA (Phase-II) * To assess ACPA seroconversion after anti-CD19 CAR T cell or rituximab therapy in subjects with active, ACPA positive and treatment refractory RA (Phase-II) Participants in the test-arm will receive a single dose of KYV-101 i.v., an autologous fully-human anti-CD19 CAR T-cell immunotherapy. In the comparator group patients will receive 2x1 g Rituximab i.v. Follow-up time (both arms) is 52 weeks with regular visits at the site.

Conditions

  • Rheumatoid Arthritis

Interventions

  • KYV101Drug

    an autologous fully-human anti-CD19 CAR T-cell immunotherapy

  • Rituximab (active comparator)Drug

    anti CD20 monoclonal antibody

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety Phase I (1) SafetyTime frame: up to week 52
  2. Safety Phase I (2) SafetyTime frame: up to 52 weeks
  3. Safety Phase I (3) SafetyTime frame: up to 52 weeks
  4. Safety Phase I (4) SafetyTime frame: up to 52 weeks
  5. Efficacy Phase IITime frame: visit week 16
  6. Safety Phase II (1)Time frame: up to 52 weeks
  7. Safety Phase II (2)Time frame: up to 52 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Charité - Universitätsmedizin Berlin

    Berlin, State of Berlin, Germany

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.